Eloxx Pharmaceuticals Inc (ELOX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2017 | 06-2017 | 03-2017 | 12-2016 | 09-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -10,596 | -6,556 | -2,678 | -1,723 | -934 |
| Depreciation Amortization | 649 | 638 | 29 | 26 | 12 |
| Income taxes - deferred | N/A | N/A | N/A | -1,040 | -640 |
| Accounts payable and accrued liabilities | -740 | -1,182 | -822 | 104 | 55 |
| Other Working Capital | 198 | -48 | -115 | 227 | 167 |
| Other Operating Activity | 821 | 1,246 | 855 | 1,395 | 767 |
| Operating Cash Flow | $-9,668 | $-5,902 | $-2,731 | $-1,012 | $-574 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -155 | -96 | -74 | N/A | N/A |
| Purchase Of Investment | N/A | N/A | -22 | N/A | N/A |
| Purchase Sale Intangibles | N/A | N/A | N/A | 50 | 50 |
| Other Investing Activity | 0 | 0 | 0 | 50 | 50 |
| Investing Cash Flow | $-155 | $-96 | $-96 | $50 | $50 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | 300 | N/A |
| Debt Issued | 2,500 | 2,500 | 2,460 | N/A | N/A |
| Other Financing Activity | 18,672 | 14,669 | 0 | 0 | 0 |
| Financing Cash Flow | $21,172 | $17,169 | $2,460 | $300 | $0 |
| Beginning Cash Position | 2,250 | 2,250 | 2,212 | 811 | 811 |
| End Cash Position | 13,599 | 13,421 | 1,845 | 149 | 287 |
| Net Cash Flow | $11,349 | $11,171 | $-367 | $-662 | $-524 |
| Free Cash Flow | |||||
| Operating Cash Flow | -9,668 | -5,902 | -2,731 | -1,012 | -574 |
| Capital Expenditure | -155 | -96 | -74 | 0 | N/A |
| Free Cash Flow | -9,823 | -5,998 | -2,805 | -1,012 | -574 |